Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

Delayed Quote. Delayed  - 07/25 10:00:23 pm
75.56 USD   -0.16%
07/25 BRISTOL MYERS S : Appoints Fouad Namouni, M.D., Oncology Development..
07/25 ABBVIE : and Bristol-Myers Squibb announce lung cancer clinical tria..
07/25BRISTOL-MYERS S : half-yearly earnings release
News SummaryMost relevantAll newsSector news 

Bristol-Myers Gets SEC Subpoena In Foreign Bribery Probe

share with twitter share with LinkedIn share with facebook
share via e-mail
04/26/2012 | 07:01pm CEST
   By Peter Loftus 

Drug maker Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) said it has received a subpoena from the U.S. Securities and Exchange Commission as part of an investigation into bribery overseas.

Bristol-Myers said the subpoena received in March seeks information related to sales and marketing practices in "various countries."

The New York-based company said in a quarterly report filed Thursday with the SEC that it was cooperating with the government. A spokeswoman declined comment beyond the information in Thursday's SEC filing.

Bristol-Myers, which sells the anti-clotting drug Plavix, previously disclosed that the SEC was investigating the activities of the company's units in Germany, concerning potential violations of the U.S. Foreign Corrupt Practices Act, or FCPA.

U.S. authorities in recent years have stepped up enforcement of the FCPA, which bars U.S. companies from bribing foreign officials to obtain or retain business. Multinational drug and medical-device makers based in the U.S. have been among the targets of enforcement.

Last year, Johnson & Johnson (>> Johnson & Johnson) agreed to pay nearly $80 million to resolve allegations that it paid bribes to doctors in three European countries, as well as kickbacks to Iraq to illegally obtain business under former leader Saddam Hussein.

Other drug makers--including Pfizer Inc. (>> Pfizer Inc.), Merck & Co. (>> Merck & Co., Inc.) and Eli Lilly & Co. (>> Eli Lilly & Co.)--also have been the subjects of federal inquiries regarding the FCPA.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
07/25 BRISTOL MYERS SQUIBB : Appoints Fouad Namouni, M.D., Oncology Development Head
07/25 ABBVIE : and Bristol-Myers Squibb announce lung cancer clinical trials collabora..
07/25BRISTOL-MYERS SQUIBB CO : half-yearly earnings release
07/25 ABBVIE : and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Ev..
07/25 BRISTOL MYERS SQUIBB : CHMP Issues Positive Opinion for ORENCIA® (abatacept) in ..
07/21 REPORTS SUMMARIZE PHARMACOKINETICS F : The Segregated Flow Model for Intestinal ..
07/21 BRISTOL MYERS SQUIBB : Reports Outline Hepatitis C Virus Study Results from Bris..
07/20 BRISTOL MYERS SQUIBB : Announces Availability of FDA-Approved ORENCIA® (abatacep..
07/18 BRISTOL MYERS SQUIBB : Announces Regulatory Updates for Opdivo (nivolumab) in Pr..
07/14 BRISTOL MYERS SQUIBB : Acquires Cormorant Pharmaceuticals
More news
Sector news : Pharmaceuticals - NEC
07/25DJGilead Sales of Hepatitis C Drugs Fall 19%
07/25DJSTADA ARZNEIMITTEL : Feels More Heat From Active Ownership
07/25DJASTRAZENECA : 2Q 2016 -- Forecast
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/25 European Ad Comm backs expanded use of Bristol-Myers' Orencia in RA patients ..
07/25 AbbVie teams up with Bristol-Myers in combo treatment for lung cancer
07/25 Game Plan For The Week - Cramer's Mad Money (7/22/16)
07/24 TOP 10 HEALTH CARE STOCKS : Which To Buy? Part 3
07/21 The Perfect Dividend Portfolio
Financials ($)
Sales 2016 18 580 M
EBIT 2016 4 900 M
Net income 2016 4 106 M
Debt 2016 814 M
Yield 2016 2,05%
P/E ratio 2016 30,43
P/E ratio 2017 24,26
EV / Sales 2016 6,83x
EV / Sales 2017 6,00x
Capitalization 126 133 M
More Financials
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 77,0 $
Spread / Average Target 1,9%
Consensus details
EPS Revisions
More Estimates Revisions
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.58%343 528
PFIZER INC.13.94%223 065
NOVARTIS AG-5.13%218 815
ROCHE HOLDING LTD.-9.62%217 668
MERCK & CO., INC.10.87%162 096
More Results